SEASTAR MEDICAL HOLDING CORPORATION - COMMON STOCK

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Support SeaStar Medical’s Proposals to Ratify the Issuance of Shares and to Reduce the Number of Authorized Shares

22 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Reaches Milestone of 100th QUELIMMUNE Commercial Device as Shipments Begin to its Third Hospital Customer

15 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Reports Third Quarter 2024 Financial Results and Provides a Business Update

13 Nov 2024 16:05:22 By Nasdaq GlobeNewswire

FDA Grants Breakthrough Device Designation for SeaStar Medical’s Selective Cytopheretic Device for Adults Undergoing Chronic Dialysis

06 Nov 2024 08:00:00 By Nasdaq GlobeNewswire

Record Monthly Enrollment Achieved in SeaStar Medical’s Pivotal Adult AKI Trial

01 Nov 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Adds Second Hospital Customer for QUELIMMUNE

31 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024 - Update

25 Oct 2024 10:32:00 By Nasdaq GlobeNewswire

Economic Analysis Supporting Significant Hospitalization Cost Reduction with SeaStar Medical’s QUELIMMUNE Pediatric Therapeutic Device Presented at ASN Kidney Week 2024

25 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Announces that Stanford Medicine is Cleared to Actively Enroll Subjects in the Adult Acute Kidney Injury Pivotal Trial

23 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical to Distribute QUELIMMUNE Directly to Hospital Customers

22 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Announces that Enrollment in its Adult Acute Kidney Injury Pivotal Trial Has Exceeded the Halfway Point Toward an Interim Analysis

18 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical to Showcase New Mechanistic Data Highlighting the Immunomodulatory Effect of the Selective Cytopheretic Device in Acute Kidney Injury at ASN Kidney Week

15 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical to Present at the 2024 Maxim Healthcare Virtual Summit

09 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Expands NEUTRALIZE-AKI Pivotal Trial Adding Two Premier Military Medical Facilities

08 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Reports Enrollment Momentum in Its Pivotal Adult AKI Trial

25 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical to Webcast Fireside Chat at the H.C. Wainwright Global Investment Conference

05 Sep 2024 07:00:00 By Nasdaq GlobeNewswire

SeaStar Medical Strengthens Financial Position with Elimination of All Long-Term Debt

04 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

SeaStar Medical Reports Second Quarter 2024 Financial Results and Provides a Business Update

13 Aug 2024 15:38:00 By Nasdaq GlobeNewswire

First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device

23 Jul 2024 07:30:00 By Nasdaq GlobeNewswire

CMS Grants Category B Coverage for Adults with Acute Kidney Injury Enrolled in SeaStar Medical’s Selective Cytopheretic Device Pivotal Trial

16 Jul 2024 07:30:00 By Nasdaq GlobeNewswire